Eccogene, a clinical-stage biopharmaceutical company, has announced enrollment of the first patient in MOSAIC, a Phase 2a clinical trial investigating two novel oral small molecules for treating metabolic dysfunction-associated steatohepatitis…
GSK announced a significant milestone in respiratory medicine as the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Nucala (mepolizumab) for treating uncontrolled…
Eli Lilly presented compelling clinical evidence positioning its BTK inhibitor Jaypirca as a potentially superior treatment option compared to the established blood cancer therapy Imbruvica, marking a significant competitive shift…
The biotech sector witnessed significant momentum as four clinical-stage companies announced compelling data across muscular dystrophy, immunology, and obesity treatment areas, triggering substantial stock market gains and investor enthusiasm for…
Genentech announced landmark clinical trial results demonstrating that giredestrant, an investigational selective estrogen receptor degrader (SERD), significantly outperforms standard endocrine therapy in treating early-stage ER-positive breast cancer. As reported by…
Parabilis Medicines has achieved a significant milestone in cancer drug development, receiving FDA Fast Track designation for FOG-001, a groundbreaking first-in-class therapy targeting desmoid tumors. As reported by Drugs.com, this…
In a significant development for neurodegenerative disease treatment, BioPharma Dive reports that AC Immune has unveiled compelling evidence that its novel immunological strategy may fundamentally alter how the medical community…
An experimental cancer vaccine from the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy has delivered encouraging results in a phase I trial for fibrolamellar carcinoma…
Researchers at the University of Southampton have uncovered a hidden culprit in blood cancer, a unique sugar molecule that disguises aggressive lymphoma cells and renders them resistant to conventional treatments.…
A new artificial intelligence model, popEVE, could accelerate diagnoses for rare, single-variant genetic diseases by scoring how likely each genetic change in a patient’s genome is to cause disease. Developed…
University of Southampton researchers have identified a distinct subtype of diffuse large B‑cell lymphoma (DLBCL), termed “Mann-type DLBCL,” marked by a unique mannose sugar on the B‑cell receptor that fuels…
Three-year-old Oliver Chu has stunned clinicians after becoming the first person with Hunter syndrome (MPS II) to receive an experimental gene therapy and showing striking early gains. Hunter syndrome is…
Hundreds more patients in England with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) will gain earlier access to glofitamab (Columvi) after new guidance from the National Institute for Health…
Vera Therapeutics has taken a major step toward transforming treatment for immunoglobulin A nephropathy (IgAN), submitting a Biologics License Application to the U.S. Food and Drug Administration through the Accelerated…
Arrowhead Pharmaceuticals has secured its first U.S. approval with Redemplo, an RNA interference therapy cleared by the FDA for adults with familial chylomicronemia syndrome (FCS). Used alongside dietary management, as…
See additional Important Safety Information below. Please read the accompanying full Prescribing Information, including Boxed WARNING, also available at NUPLAZID.com. You are encouraged to report negative side effects of prescription…
Maple syrup urine disease (MSUD) represents one of medicine's most deceptive challenges, a rare inherited metabolic disorder where patients can appear dangerously well while their brains swell dangerously. As reported…
The NHS has dramatically expanded access to a life-saving cancer therapy, according to NHS England, offering approximately 300 blood cancer patients in England annually a genuine chance at complete remission.…
A groundbreaking achievement in genetic medicine has emerged as the European Medicines Agency (EMA) recommended approval of Waskyra (etuvetidigene autotemcel), the first gene therapy specifically designed to treat Wiskott-Aldrich syndrome…
Hypereosinophilic syndrome (HES) patients may finally have a meaningful treatment option. According to an article published at BusinessWire.com, AstraZeneca's FASENRA (benralizumab) has shown statistically significant efficacy in delaying disease progression,…
Tonix Pharmaceuticals announced plans to initiate Phase 2 clinical trials in 2026 for TNX-2900, an innovative intranasal oxytocin formulation designed to treat Prader-Willi Syndrome (PWS), a rare genetic disorder characterized…
Takeda Pharmaceutical Company announced promising interim data from a Phase 1b clinical trial demonstrating that mezagitamab (TAK-079), an experimental immunotherapy, maintains kidney function stability for extended periods even after treatment…
Biohaven Pharmaceuticals faced a significant setback when the U.S. Food and Drug Administration issued a Complete Response Letter (CRL) rejecting the company's New Drug Application for Vyglxia (troriluzole), a promising…
The U.S. Food and Drug Administration has approved UCB's Kygevvi, marking a historic milestone for patients with thymidine kinase 2 deficiency (TK2d), an ultra-rare inherited mitochondrial disorder that has lacked…
Editor’s Note: This story is a continuation of Jenny Decker’s global sailing voyage. To see the original article, please click here. Jenny Decker's journey called “Just a Lap" continues. Patient…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
